Cell Wall News and Research

RSS

Another step forward in the battle against bacterial infections

Bacterial infections can strike anyone, and they can sometimes be fatal. Because more and more bacteria are becoming resistant to the pre-eminent remedy; antibiotics; the search for new remedies against bacterial infections is in high gear.

12 Feb 2006

Advance in the fight against bacterial infections

Bacterial infections can strike anyone, and they can sometimes be fatal. Because more and more bacteria are becoming resistant to the pre-eminent remedy - antibiotics - the search for new remedies against bacterial infections is in high gear.

2 Feb 2006

Significant relationships between household endotoxin and diagnosed asthma

Exposure to household endotoxin levels poses a significant risk for asthma, according to the first nationwide sampling of house dust.

2 Dec 2005

Water management is the key to regulating cell volume

...says Dutch researcher Bas Tomassen. He investigated the uptake and secretion of water by the plasma membrane of animal and human cells.

27 Sep 2005

New way to create a permanent chemical bond between antibiotics and titanium

Infections associated with inserting a medical device can be devastating, painful, and cause prolonged disability, costing tens of thousands of dollars.

26 Sep 2005

Antibiotic resistance has put humans in an escalating 'arms race' with infectious bacteria

...as scientists try to develop new antibiotics faster than the bacteria can evolve new resistance strategies. But now, researchers have a new strategy that may give them a leg up in the race -- reproducing in the lab the natural evolution of the bacterial enzymes that confer resistance.

21 Sep 2005

Bacteria lurking in household dust produce chemicals that may trigger asthma

These bacterial chemicals, called endotoxins, particularly those found on bedroom floors, were linked with increased respiratory problems in adults.

7 Sep 2005

Single molecular anchor holds the key to treating many types of bacterial meningitis

By blocking the molecule's anchoring ability, researchers may be able to find a way to stave off the most common serious infection of the central nervous system and a major cause of childhood death and disability. The researchers' findings appear in the September 2005 issue of the Journal of Clinical Investigation.

5 Sep 2005

New vaccine with the potential to protect against fungal pathogens

A group of scientists in Italy have developed a vaccine with the potential to protect against fungal pathogens that commonly infect humans, according to a study by Torosantucci and colleagues in the September 5 issue of The Journal of Experimental Medicine.

5 Sep 2005

New drug will help fight against superbugs

In the fight against the infections invading hospitals both sides of the globe, scientists have developed a drug that destroys the defences of superbugs, raising hopes it could help quell the rampant and often lethal outbreaks that continue to strike hospitals.

4 Sep 2005

Unusual type of antibiotic shows promise in defeating deadly "superbugs"

An unusual type of antibiotic being developed by chemists at Notre Dame University shows promise in defeating deadly "superbugs" - highly drug-resistant staph bacteria that are an increasing source of hospital-based infections.

29 Aug 2005

Lipid helps cell wall protein fold into proper shape

A protein that provides a vital passage through a bacterium's outer cell wall will misfold and malfunction if that wall is built of the 'wrong' material, scientists at The University of Texas Medical School at Houston report in a finding that has long-term implications for understanding diseases caused by misfolded proteins such as cystic fibrosis, Alzheimer's disease, and mad cow disease.

17 Jul 2005

Bioniche Life Sciences granted European patent

Bioniche Life Sciences has announced that it has had another patent granted on its core technology: Mycobacterial Cell Wall-DNA Complex (MCC). The European Patent Organization (EPO) granted the patent: - "Composition and Method for Inducing Apoptosis in Prostate Cancer Cells" (EPO1165106)

30 May 2005

Flavonols in food, key to healthy eating?

University of Melbourne scientists may have found the secret of the fresh fruit and vegetables centred ‘Mediterranean diet’.

29 May 2005

Bioniche granted additional patent for mycobacterial cell wall technology

Bioniche Life Sciences Inc., a research-based, technology-driven human and animal health biopharmaceutical company, today announced that it has had a new patent issued by the United States Patent and Trademark Office (USPTO) on its core mycobacterial cell wall technology.

18 May 2005

Cancer patients may one day benefit from treatment with mixtures of customized antibodies

In a study published recently in the Proceedings of the National Academy of Sciences (USA), a team of Weizmann Institute scientists have demonstrated how the right combination might form a web that destroys the cancer cell's communication network, ultimately demobilizing the cell.

22 Apr 2005

Bioniche receives European patent

Bioniche Life Sciences Inc., a research-based, technology-driven human and animal health biopharmaceutical company, today announced that it has had an additional European patent granted by the European Patent Office (EPO) on its core mycobacterial cell wall technology.

29 Mar 2005

New immunotherapeutic approach against anthrax

The anthrax attacks in the aftermath of September 11, 2001 in the USA have illustrated the high potential of anthrax for misuse in bio-terrorism. Dissemination of anthrax by letters led to the death of 5 people and chemotherapeutic treatment of 30,000 individuals.

15 Mar 2005

Discovery may provide a new target to treat sepsis

Part of the immune system's pro-inflammatory response to bacterial invasion is to increase nitric oxide levels with an enzyme called inducible nitric oxide synthase.

14 Mar 2005

Research breakthrough in treatment of TB and MDR-TB

FASgen Inc.'s compound, FAS20013, has emerged from an intense multi-year program of pre-clinical studies that clearly validate its potential as an ideal new drug for the treatment of tuberculosis and MDR-TB, the disease caused by organisms that are resistant to the drugs now commonly used to treat TB. Initial clinical trials in both TB and MDR-TB are scheduled for later this year.

12 Jan 2005